Abstract Systemic adjuvant therapy for surgically resected cutaneous melanoma that is at high risk for disease recurrence and death targets residual micrometastatic disease which is the source of future local or distant relapse. Interferon-alfa (IFNα) has been the most extensively studied in regimens that varied by dosage, route of administration, formulation, and duration of therapy. Most regimens have demonstrated improvements in relapse-free survival (RFS), while the regimen administered at high dosage (HDI) showed improvements in overall survival (OS) in two out of three RCTs. HDI benefits as measured by the hazard ratios (HR) in E1684 (vs. observation), E1690 (vs. observation), and E1694 (vs. vaccine) trials were estimated at 0.61, 0.78, and 0.67 (RFS) and 0.67, 1.0, and 0.72 (OS) when first reported with lesser estimates on later updates. Pegylated IFNα (peg-IFN) as studied in the European Organisation for Research and Treatment of Cancer (EORTC) 18991 trial in patients with stage III melanoma significantly reduced the risk of relapse (HR 0.87) with no impact on OS. More recently (EORTC 18071), ipilimumab at the high dose of 10 mg/kg was shown to significantly improve RFS (HR 0.76) and OS (HR 0.72) of stage III melanoma patients but at a significant cost in terms of immune-related toxicities. Ongoing adjuvant studies are testing ipilimumab at 3 or 10 mg/kg versus HDI (E1609) and the anti-PD-1 antibodies nivolumab (CheckMate 238) and pembrolizumab (KEYNOTE-054 and S1404).
Introduction
Over 9000 patients die from malignant melanoma annually in the USA [1] . Almost all of these deaths are attributed to metastatic disease following primary surgical management failure at achieving cure. Surgery remains the only curative treatment for melanomas with early presentation and low-risk features. High-risk melanoma, on the other hand, has a high surgical failure rate, where systemic adjuvant therapy is indicated in order to reduce the rate of recurrence and subsequent death. Of all the adjuvant treatment modalities tested, immunotherapy has emerged to be the most effective and has continued to expand, resulting in significant improvements in the outcomes of high-risk melanoma patients.
Clinical Staging of Melanoma and the Impact on Disease Recurrence and Survival
The American Joint Committee on Cancer (AJCC) staging system for melanoma takes into account several prognostic factors [2] . Stages I and II are defined as melanoma confined to the skin only with no lymphatic involvement or distant organ metastasis. The primary tumor depth and the presence or absence of ulceration defines different subcategories of stages I and II. The presence of lymph node or in-transit lymphatic involvement indicates stage III. Distant organ metastases are representative of stage IV.
An increase in primary tumor depth or the presence of ulceration or a high mitotic rate is correlated with a decrease in survival. Furthermore, the presence of lymphatic metastasis conveys a worse prognosis that declines as the number of This article is part of the Topical Collection on Melanoma involved lymph nodes increases [2] . Among patients with stage IV melanoma, patients with nodal or cutaneous metastasis (M1a) have a better prognosis than those with lung (M1b) or other visceral metastasis (M1c). A high serum LDH level among patients with any stage IV disease is a marker of high tumor burden and worse prognosis (M1c) [2] .
Patients who are expected to benefit the most from systemic adjuvant therapy are those with melanoma presenting as stages IIB-III, where the risk of relapse ranges from approximately 40-90% [2, 3] . Here, postoperative systemic adjuvant therapy targets micrometastatic disease which is the source of future relapse and possibly provides the greatest opportunity at achieving cure before progression into more advanced stages.
Adjuvant Immunotherapy with Interferon Alpha
Interferon alpha-2 (IFNα) has been studied extensively in the adjuvant setting in melanoma with one study evaluating its activity as a neoadjuvant therapy [4] . Mechanistic studies conducted within the IFNα neoadjuvant study demonstrated its ability to induce an influx of dendritic cells and T lymphocytes into nodal tumor tissue, while STAT 3 (signal transducer and activator of transcription) expression in the tumor cells was downregulated, therefore reversing immune tolerance mediated by STAT 3 upregulation by tumor cells. IFNα also induced STAT 1 upregulation allowing reversal of T cell signaling defects [5] . Table 1 summarizes the major phase III trials that tested adjuvant IFNα therapy in surgically resected melanoma.
Adjuvant Studies Investigating High-Dose IFNα
The Eastern Cooperative Oncology Group (ECOG) E1684 landmark trial led to the Food and Drug administration (FDA) approval of high-dose IFNα (HDI) as an adjuvant treatment for high-risk surgically resected malignant melanoma in 1995. In this study, 287 patients were randomized to either the HDI treatment group or observation alone. This regimen began with an induction phase, which was given at 20 MU/m 2 of IFNα intravenously for 5 consecutive days a week for 4 weeks followed by a maintenance phase, which was administered as a subcutaneous injection of 10 MU/m 2 three times a week for 48 weeks. With a median follow-up of 6.9 years, the 5 year relapse-free survival (RFS) rate was 37% (95% confidence interval (CI), 30-46%) in the treatment arm compared to 26% (95% CI, 19-34%) in the observation arm. The results also showed a 5-year overall survival (OS) rate of 46% (95% CI, 39-55%) in the treatment arm versus 37% (95% CI, 30-46%) in the observation arm [5] . Median RFS was 1.72 versus 0.98 years (p = 0.0023) for a hazard ratio (HR) of 0.61 (p = 0.0013), and median OS was 3.82 versus 2.78 years (p = 0.0237), HR = 0.67 (p = 0.01). Patients with pathologically positive lymph node involvement (N1 disease) appeared to have the highest survival benefit. However, HDI treatment resulted in a fairly significant toxicity profile, with the incidence of grades 3 and 4 toxicity being 67 and 9%, respectively, and including two early therapy-related hepatotoxic deaths [7••] . This led to several later trials designed to reduce HDI toxicity profile by lowering the administered dose.
The E1690 RCT, which tested HDI and low-dose interferon (LDI; 3 MU subcutaneous (SC) thrice weekly for 2 years) failed to show an OS benefit from either regimen versus observation alone [8] . After a median follow-up of 4.3 years, the estimated 5-year RFS rates were 44% for HDI, 40% for LDI, and 35% for observation, respectively [8] . The benefits of HDI in RFS was significant (P = .03). However, unlike E1684, there was no requirement for elective lymph node dissection in E1690, and a retrospective analysis of E1690 suggested a crossover of 38 patients following regional nodal relapse on observation to HDI salvage therapy that may have affected the survival analysis.
The US Intergroup E1694 trial tested adjuvant therapy with a ganglioside vaccine (GMK) versus HDI. The GMK vaccine was made of purified ganglioside GM2 coupled to keyhole limpet hemocyanin (KLH) combined with the adjuvant QS-21. Prior studies of GMK had demonstrated its immunogenicity and suggested evidence of clinical activity. HDI was superior to GMK in RFS (HR = 0.68; p = 0.0015) and OS (HR = 0.66; p = 0.009) in the study's eligible high-risk adjuvant population. Similar results were observed in the intent-to-treat analysis for RFS (HR = 0.67) and OS (HR = 0.72) [9, 21] .
A pooled analysis of E1684 and E1690 (the two observation-controlled trials) that was updated through April 2001 concluded that there were significant benefits in RFS in favor of HDI at the long-term median follow-up of 12.6 years for E1684 and 6.6 years for E1690 [22] . On the other hand, the analysis showed no significant benefits in OS benefit for HDI. This was not surprising since E1690 (the larger of the two trials) did not show an OS benefit for HDI. Furthermore, the long-term follow-up in E1684, median of 12.6 years, suggested the potential impact of competing causes of death on the OS analysis in that study's population [7••, 8, 9, 22] . The pooled analysis did not include E1694 (GMK vaccine rather than observation was the control arm vs. HDI).
In addition to the three prior RCTs, adjuvant therapy with HDI was tested in a randomized phase II trial that enrolled 107 patients with surgically resected stages IIB, III, and IV melanoma, E2696 [23] . The primary objective of E2696 was to investigate the immunogenicity of the GMK vaccine in the presence or absence of HDI, measuring the anti-GM2 serologic response. The study consisted of three arms including arm A (GMK with concurrent HDI), arm B (GMK with sequential HDI), and arm C (GMK alone). Clinically, there was [17] significant RFS benefit in the HDI combination arms versus GMK vaccine monotherapy (HR = 1.75 for C vs. A and 1.96 for C vs. B). The Hellenic Oncology Group HE13A/98 study randomized patients to a modified induction phase of 15 MU/m 2 IVof HDI only versus the same induction phase followed by a modified maintenance phase of 10 MU SC flat dose (not per square meter) three times a week for a year [24] . This study showed no statistically significant differences in RFS or OS between the 1-month and 1-year regimens, but was criticized for its small sample size (182 patients per arm), the lower induction phase daily dose and the flat and lower dosing of the modified maintenance phase in reference to the standard HDI regimen.
The E1697 study targeted patients with intermediate risk melanoma (≥T3 or any thickness with microscopic nodal disease N1a-N2a). The study enrolled 1150 patients who were randomized to either 4 weeks of HDI 20 MU/m2 given IV per day for 5 days weekly (mirroring the E1684 induction phase) versus observation [25] . This study failed to demonstrate any relapse of survival benefits from the 4-week HDI regimen and therefore was closed to accrual for futility after a third interim analysis. [20] and the French Multicenter Trial [14] . On the other hand, RFS benefits were consistently seen in the majority of these trials.
Adjuvant Studies Testing Varying Dosing Levels of IFNα
The EORTC 18952 trial investigated two different maintenance regimens following an induction phase of IFNα at 10 MU IV five times a week for 4 weeks. In this study, 1388 patients were randomized to receive either SC IFNα at 10 MU three times a week for 1 year versus SC IFNα at 5 MU 3 days a week for 2 years versus observation alone [11] . After a median follow-up of 4.65 years, there was a trend for increased disease-free survival and overall survival of 7.2% (HR 0.83, 97.5% CI 0.66-1.03) and 5.4% (HR 0.85, 97.5% CI 0.68-1.07), respectively, in favor of the 2-year regimen. However, these trends were both statistically insignificant. Yet these results suggested that duration of the therapy with IFNα may play a greater role than dosage.
The Dermatological Group trial (DeCOG) attempted to enhance the IFNα efficacy in the adjuvant setting by adding cytotoxic chemotherapy (dacarbazine) to LDI and comparing this regimen to LDI alone. The results of the trial showed improvement in disease-free survival (HR = 0.69) and overall 
Meta-analyses of RCTs Testing Adjuvant IFNα
Four meta-analyses of RCTs of adjuvant IFNα trials in highrisk melanoma have supported IFNα adjuvant therapy benefits [26] [27] [28] [29] . Mocellin et al. reported a meta-analysis that reviewed the RFS and OS benefits of IFNα in the adjuvant setting and included 8122 patients and 14 RCTs. This metaanalysis came to the conclusion that adjuvant IFNα showed a statistically significant decrease in the risk of recurrence of 18% (HR = 0.82, 95% CI 0.77-0.87, p < 0.001) and a decreased risk of death of 11% (HR = 0.89, 95% CI 0.83-0.96, p = 0.002) [28] . A more recent meta-analysis was the Cochrane Analysis of Adjuvant Melanoma Trials that included 17 RCTs of adjuvant IFNα and a total of 10,499 patients [29] . In reviewing RFS benefits, HR of 0.83 (0.78-0.87) was found corresponding to 17% reduction in risk. In the OS analysis, HR of 0.91 (0.85-0.97) was concluded corresponding to a 9% reduction in risk. Table 2 summarizes these results.
Chemotherapy as Adjuvant Therapy in Melanoma
A number of studies investigated the potential benefits of chemotherapy in the adjuvant setting including dacarbazine (DTIC) and levamisole, but have not been able to show any significant benefits in disease-free survival or overall survival for chemotherapy alone or in combination with other agents [30] [31] [32] [33] .
Biochemotherapy Adjuvant Therapy Trials in Melanoma
Phase III studies have examined biochemotherapy regimens as adjuvant therapy in high-risk surgically resected melanoma. The S0008 study conducted by the South West Oncology Group (SWOG) compared a 9-week biochemotherapy regimen consisting of 3 cycles of cisplatin, vinblastine, DTIC, and low doses of IL-2 and IFNα versus the 52-week HDI E1684 regimen [34] . After 7.2 years of median follow-up, Flaherty et al. reported an i mprovement in RFS for the biochemotherapy arm versus the HDI arm (median RFS of 4.0 years vs. 1.9 years, respectively; HR 0.75; 95% CI, 0.58-0.97; p = 0.015). However, S0008 did not demonstrate an improvement in OS (56% 5-year OS rate for both). In terms of adverse events, the biochemotherapy arm had a higher toxicity rate than the HDI arm (grade III/IVadverse events reported at 76 vs. 64%).
Adjuvant Immunotherapy with Vaccines
Vaccine adjuvant therapy studies in melanoma tested whole cells/cell lysates, peptide vaccines, and ganglioside antigen vaccines, but have generally been unsuccessful in demonstrating significant benefits in the adjuvant setting. The DERMA trial tested adjuvant therapy with the MAGE-A3 protein [35] . Melanoma antigen A (MAGE-A) proteins are a subfamily of cancer/testis antigens that are expressed in several malignancies including melanoma. The study sought to show a benefit from adjuvant MAGE-A3 plus AS15 immunostimulant administration but failed to show benefits in the primary endpoint of RFS. Other studies examined vaccines as therapy methods and also failed to show a benefit [23, 36] . RFS relapse-free survival, OS overall survival, HR hazard ratio, NNT number needed to treat to prevent one event
Antiangiogenic Adjuvant Therapy with Bevacizumab
A phase III trial, AVAST-M, investigated bevacizumab versus observation as adjuvant therapy within patients with surgically resected AJCC stages II and III melanoma [37] . After 25 months of median follow-up, no significant differences in OS or distant metastasis-free survival were seen. A modest improvement in the disease-free interval in favor of bevacizumab was reported (HR 0.83; 95% CI 0.70-0.98; p = 0.03).
Adjuvant Immunotherapy with the Anti-CTLA4 Antibody Ipilimumab
Ipilimumab has been approved by the FDA as a form of treatment for both metastatic melanoma at the dose of 3 mg/kg and high-risk surgically resected stage III melanoma at the dose of 10 mg/kg. In metastatic melanoma, ipilimumab was investigated in the MDX10-20 trial, which randomized participants to an ipilimumab-only arm at a dose of 3 mg/kg every 3 weeks for four doses, ipilimumab and a peptide vaccine group, and finally a vaccine and placebo group [38] . The results demonstrated that ipilimumab provided a significant survival advantage over the vaccine group leading to regulatory approval. Survival benefits were also seen with ipilimumab at 10 mg/kg combined with dacarbazine versus dacarbazine alone (CA 184-024) [39] . The EORTC 18071 trial tested adjuvant therapy with ipilimumab at 10 mg/kg I.V. every 3 weeks for four doses then every 3 months for up to 3 years versus placebo [40] . It enrolled melanoma patients with stages IIIA (N2a), IIIB, and IIIC (except in-transit disease). When first reported at a median follow-up of 2.7 years, the study met its primary endpoint of RFS. Median RFS reported at 26.1 months (95% CI 19.3-39.3) versus 17.1 months (95% CI 13.4-21.6). The HR was 0.75; 95% CI 0.64-0.90; p = 0.0013. As expected, adjuvant ipilimumab at 10 mg/kg was associated with significant toxicity, including grade 3/4 gastrointestinal adverse events (16 vs. <1%), liver (11 vs. < 1%) and endocrine (8 vs. 0%) events. The toxicity of ipilimumab at 10 mg/kg continues to pose a major challenge to the adoption of ipilimumab at 10 mg/kg as an adjuvant therapy in a community setting. E1609 is a phase III trial lead by ECOG-ACRIN and the U.S. Intergroup and is testing adjuvant therapy with ipilimumab at 3 or 10 mg/kg versus HDI [NCT01274338]. This study completed accrual in August 2014 and enrolled surgically resected melanoma patients with stages IIIB, IIIC (including in-transit disease), M1a and M1b. RFS and OS are the two coprimary endpoints of the trial. This study will answer the key questions related to the risk-to-benefit ratio of the two ipilimumab dose levels as compared to HDI and whether ipilimumab is superior as an adjuvant therapy. E1609 also has an associated biomarker project investigating biomarkers of prognostic and therapeutic predictive value that may further guide the adjuvant therapy of melanoma.
Ongoing Adjuvant Therapy Trials
Adjuvant Immunotherapy with Anti-PD-1 Antibodies Programmed Death 1 (PD-1) physiology plays an important role in tumor immunology where PD-1 receptors expressed by T cells downregulate their effector phase response playing a role in mediating tumor immune tolerance [42] . The anti-PD-1 antibodies nivolumab and pembrolizumab have demonstrated significant benefits in RFS and OS in the treatment of metastatic melanoma that are superior to ipilimumab, both as monotherapy and in combination with ipilimumab [43] [44] [45] . Ongoing RCTs are studying PD-1 blockade as adjuvant therapy in high-risk surgically resected melanoma. These trials include CheckMate-238 that is testing nivolumab versus ipilimumab 10 mg/kg and completed accrual in 2015. KEYNOTE-054 is testing pembrolizumab versus placebo while the U.S. Intergroup trial S1404 is investigating pembrolizumab versus the choice of either HDI or ipilimumab at 10 mg/kg.
Adjuvant Targeted Therapy with Inhibitors of BRAF and MEK
A common mutation observed in about 40-50% of melanomas is a substitution mutation on BRAF, whose normal role is to act as a kinase for MEK1 and MEK2. Loss of this regulation from BRAF causes activation of the MAPK/ERK pathway and ultimately tumor growth and survival. The V600E mutation in which glutamic acid substitutes for valine at the V600 locus accounts for 80-90% of BRAF mutations in melanoma. In patients with metastatic melanoma, the BRAF-MEK inhibitors dabrafenib-trametinib (Novartis) and vemurafenib-cobimetinib (Genentech-Roche) received regulatory approval after demonstrating significant improvements in RFS and OS in this patient population [46, 47] . As an adjuvant therapy, BRIM-8 is an RTC testing adjuvant vemurafenib versus placebo melanoma patients with stages IIC and III BRAF V600 mutation-positive melanoma (NCT01667419). Also, COMBI-AD is an RCT testing adjuvant therapy with dabrafenib-trametinib versus placebo in patients with stage III BRAF V600E/K mutation-positive melanoma (NCT01682083). The results of both studies have not been reported as of the fall of 2016, but are anticipated.
Adjuvant Radiation Therapy in High-Risk Melanoma
Radiotherapy in the management of primary cutaneous melanoma is rarely indicated. However, evidence supports a role for adjuvant therapy in surgically resected melanoma that is considered in the highest risk category for local or regional relapse after definitive surgical management. Studies of adjuvant radiation therapy have mostly demonstrated benefits in reducing the risk of local relapse with no significant improvements in RFS or OS [48] [49] [50] [51] .
A retrospective study of 160 patients with regionally advanced melanoma who underwent surgical management followed by adjuvant radiotherapy (30 Gy in 6 Gy fractions two times per week) reported improvements in local, regional, and locoregional disease control [48] . Another retrospective study concluded a reduction in the regional recurrence rate for surgery plus adjuvant radiotherapy versus surgery alone [49] . A later retrospective study by Strojan et al. also reported a significant improvement in local relapse among melanoma patients with regionally advanced disease to the neck and/or parotid [50] . More recently, an RCT (ANZMTG 01.01/TROG 02.01) tested adjuvant radiotherapy (48 Gy in 20 fractions) versus observation [51] . The study enrolled 217 patients with nodal metastases and features of high risk of recurrence following lymphadenopathy. The high-risk criteria included the number of lymph nodes involved, presence of extra-nodal tumor extension and the size of involved lymph nodes. At 40 months of median follow-up, there was an improvement in the risk of lymph-node field relapse (HR 0.56, 95% CI 0.32-0.98; p = 0.041). On the other hand, there were no statistically significant differences in OS or RFS reported.
Conclusions
As adjuvant therapy for patients with surgically resected highrisk melanoma, significant benefits have been reported in RCTs that tested IFNα and ipilimumab leading to the regulatory approval in the USA of HDI, pegylated IFN, and ipilimumab at 10 mg/kg. HDI was reported to have significant improvements in RFS in three trials (E1684, E1690, and E1694) and OS in two out of three RCTs (E1684 vs. observation and E1694 vs. GMK ganglioside vaccine). Peg-IFN as tested in the EORTC 18991 trial achieved modest improvements in the primary endpoint of RFS in stage III disease, but not in OS. EORTC 18071 demonstrated significant RFS and OS benefits with adjuvant ipilimumab at 10 mg/kg, but at the cost of significant immune-related toxicity. The U.S. Intergroup trial E1609 is investigating ipilimumab at 3 or 10 mg/kg as compared to HDI and completed accrual in August 2014. Other ongoing adjuvant trials are testing BRAF/MEK inhibitors in patients with BRAF mutant melanoma (COMBI-AD and BRIM-8) and the anti-PD-1 antibodies pembrolizumab (S1404 and KEYNOTE-054) and nivolumab (CheckMate-238).
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